Sichuan Kelun Pharmaceutical Co Ltd - Asset Resilience Ratio
Sichuan Kelun Pharmaceutical Co Ltd (002422) has an Asset Resilience Ratio of 4.41% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2025)
This chart shows how Sichuan Kelun Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Check 002422 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Sichuan Kelun Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Sichuan Kelun Pharmaceutical Co Ltd (002422) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.82 Billion | 4.41% |
| Total Liquid Assets | CN¥1.82 Billion | 4.41% |
Asset Resilience Insights
- Limited Liquidity: Sichuan Kelun Pharmaceutical Co Ltd maintains only 4.41% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Sichuan Kelun Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Sichuan Kelun Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 7.83% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
|
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
SHE:300357 |
Drug Manufacturers - General | 9.91% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
Annual Asset Resilience Ratio for Sichuan Kelun Pharmaceutical Co Ltd (2011–2025)
The table below shows the annual Asset Resilience Ratio data for Sichuan Kelun Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.66% | CN¥1.46 Billion ≈ $213.17 Million |
CN¥39.83 Billion ≈ $5.83 Billion |
-1.49pp |
| 2024-12-31 | 5.15% | CN¥1.92 Billion ≈ $281.13 Million |
CN¥37.32 Billion ≈ $5.46 Billion |
+0.51pp |
| 2023-12-31 | 4.64% | CN¥1.69 Billion ≈ $247.46 Million |
CN¥36.45 Billion ≈ $5.33 Billion |
+3.33pp |
| 2022-12-31 | 1.31% | CN¥448.11 Million ≈ $65.57 Million |
CN¥34.21 Billion ≈ $5.01 Billion |
+0.17pp |
| 2021-12-31 | 1.14% | CN¥359.53 Million ≈ $52.61 Million |
CN¥31.54 Billion ≈ $4.62 Billion |
+0.31pp |
| 2020-12-31 | 0.83% | CN¥265.42 Million ≈ $38.84 Million |
CN¥32.01 Billion ≈ $4.68 Billion |
+0.88pp |
| 2019-12-31 | -0.05% | CN¥-17.22 Million ≈ $-2.52 Million |
CN¥31.49 Billion ≈ $4.61 Billion |
-0.74pp |
| 2018-12-31 | 0.68% | CN¥200.00 Million ≈ $29.27 Million |
CN¥29.34 Billion ≈ $4.29 Billion |
-1.13pp |
| 2017-12-31 | 1.81% | CN¥507.00 Million ≈ $74.19 Million |
CN¥27.99 Billion ≈ $4.10 Billion |
+1.30pp |
| 2016-12-31 | 0.51% | CN¥120.00 Million ≈ $17.56 Million |
CN¥23.41 Billion ≈ $3.43 Billion |
-0.77pp |
| 2015-12-31 | 1.28% | CN¥290.00 Million ≈ $42.44 Million |
CN¥22.58 Billion ≈ $3.30 Billion |
+1.35pp |
| 2014-12-31 | -0.07% | CN¥-14.93 Million ≈ $-2.19 Million |
CN¥21.20 Billion ≈ $3.10 Billion |
+0.06pp |
| 2013-12-31 | -0.13% | CN¥-23.88 Million ≈ $-3.49 Million |
CN¥17.95 Billion ≈ $2.63 Billion |
+0.02pp |
| 2012-12-31 | -0.15% | CN¥-22.59 Million ≈ $-3.31 Million |
CN¥14.93 Billion ≈ $2.18 Billion |
+0.02pp |
| 2011-12-31 | -0.17% | CN¥-18.02 Million ≈ $-2.64 Million |
CN¥10.47 Billion ≈ $1.53 Billion |
-- |
About Sichuan Kelun Pharmaceutical Co Ltd
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, ve… Read more